Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

Delayed Quote. Delayed  - 09/26 05:35:19 pm
0.78 EUR   -1.27%
08/30 Neovacs to present at two major Investor Conferences
08/30 NEOVACS TO PRES : The 18th Annual Rodman & Renshaw Global Investment..
08/30 NEOVACS : to present at two major Investor Conferences
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
09/20/2016 09/21/2016 09/22/2016 09/23/2016 09/26/2016 Date
0.83(c) 0.82(c) 0.79(c) 0.79(c) 0.78 Last
251 990 288 562 404 444 461 418 127 499 Volume
0.00% -1.20% -3.66% 0.00% -1.27% Change
More quotes
Financials (€)
Sales 2016 -
EBIT 2016 -11,4 M
Net income 2016 -11,2 M
Debt 2016 2,89 M
Yield 2016 -
Sales 2017 0,88 M
EBIT 2017 8,72 M
Net income 2017 -9,74 M
Finance 2017 14,5 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 0
EV / Sales2017 22,2x
Capitalization 33,9 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory, and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis, and... 
More about the company
Surperformance© ratings of Neovacs
Trading Rating : Investor Rating :
More Ratings
Latest news on NEOVACS
08/30 Neovacs to present at two major Investor Conferences
08/30 NEOVACS TO PRESENT AT TWO MAJOR INVE : The 18th Annual Rodman & Renshaw Global I..
08/30 DGAP-NEWS : Neovacs to present at two major Investor Conferences
08/30 NEOVACS : to present at two major Investor Conferences
07/19 NEOVACS : and Stellar Biotechnologies Announce Launch of Neostell, Joint Venture..
07/19 DGAP-NEWS : Neovacs and Stellar Biotechnologies Announce Launch of Neostell, Joi..
06/23 NEOVACS : EUR 8 million capital increase successfully completed
05/30 NEOVACS : to Present at Bio International Convention 2016
05/30 NEOVACS : to Present at Bio International Convention 2016
05/30 DGAP-NEWS : Neovacs to Present at Bio International Convention 2016
More news
Sector news : Biotechnology & Medical Research - NEC
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 1,70 €
Spread / Average Target 116%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS-27.32%38
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results